Blue Jet shelves ₹1,000 cr Vizag plan, CDMO pipeline shrinks to 4 projects
Management pivoted capex away from a flagship plant and disclosed a CDMO pipeline of just 4-5 projects, down from 20 active RFPs last quarter.
What's new
- Blue Jet is shelving the ₹1,000 cr Vizag capex; FY26 spend will target de-bottlenecking and environmental infra.
- CDMO pipeline has contracted from 20 active RFPs to 4-5 key projects.
- Q2 revenue of ₹161 cr was hit by ₹20-25 cr logistical delays now resolved.
Why this matters
The dual shift, abandoning a flagship expansion and revealing a thinner deal funnel, rewrites the growth narrative for a company that was scaling toward large-scale contract manufacturing. H1 margins held at 34.4%, but the capital allocation pivot signals a more cautious posture.
What we're watching
- Whether the pharma intermediate entering commercial production in 12 months fills the CDMO pipeline gap.
- How Unit 2 capacity ramp affects Contrast Media margins in H2.
- Any revised capex guidance beyond de-bottlenecking for FY27.
The full read
Blue Jet Healthcare just rewrote its capex playbook. The ₹1,000 crore Vizag expansion, a centrepiece of prior guidance, is off the table for now. In its place, FY26 spending will focus on de-bottlenecking and environmental infrastructure. That alone would have been the story. But the CDMO pipeline, which the company last discussed as 20 active RFPs, has narrowed to 4-5 key projects. One pharma intermediate is on track for commercial production within 12 months, but the headline shrinkage in the funnel is harder to ignore. Operationally, the quarter was mixed. Q2 revenue touched ₹161 crore, dragged down by ₹20-25 crore in logistical delays that have since been cleared. H1 EBITDA margin held at 34.4%, and the company posted ₹72 crore in net profit for the half-year. Contrast Media margins are expected to sit at 33-35% in H2 as Unit 2 capacity ramps. The financials hold. The growth thesis just got smaller.
Questions answered
- Why is Blue Jet walking away from the ₹1,000 cr Vizag project?
- The concall summary does not give a specific reason. Management said it is redirecting capex to de-bottlenecking and environmental infrastructure for FY26 instead of the previously announced large-scale plant.
- How much did the CDMO pipeline shrink?
- From 20 active RFPs in prior quarters to 4-5 key projects now. One pharma intermediate molecule from that pipeline is expected to enter commercial production within 12 months.
- What hit Q2 revenue?
- Logistical delays worth ₹20-25 crore. Management said the delays have since been resolved, but they weighed on the ₹161 crore Q2 topline.
- What is the H1 profitability picture?
- H1 EBITDA margin was 34.4%, and the company posted net profit of ₹72 crore for the half-year. Contrast Media margins are expected to stabilise at 33-35% in H2 as Unit 2 capacity scales up.